Clinical trials: Hunting for a stroke of luck
Fran Hunt stumbled into her office at DHMC one day last October. She'd felt fine while driving to work but started to feel strange as she walked in from the parking lot. She began veering and bumped into the door as she entered the building.
"I go in my office and I sit down and I realize I can't move my right hand, I can't move my right leg," she recalls. "If I didn't know any better, I'd think I was having a stroke," she remembers thinking. But she considered herself too healthy for that.
Then the phone rang. "My speech was slurred when I tried to speak," says Hunt. The caller, a colleague in another office, thought at first Hunt was kidding around but soon realized she was in trouble and called for help. Within minutes, Hunt was being rushed to the emergency department, where Dr. Timothy Lukovits, a neurologist who specializes in stroke, treated her right away. His team administered tissue plasminogen activator (tPA), which dissolved a blood clot that had lodged in a cerebral artery. She recovered completely. In fact, after a two-night hospital stay, she drove herself home.
But not everyone is as lucky. Stroke is the third-leading cause of death in the U.S., killing about 160,000 people a year —out of the 700,000 who suffer a new or recurrent stroke. There are about 5.5 million stroke survivors in the U.S., many with permanent disabilities.
Act: Administering tPA within three hours is one proven way to treat stroke. Rapid evaluation and treatment of stroke patients is now routine at DHMC, thanks to a "stroke alert" system. When the
emergency department gets word a stroke victim is en route, staff are prepared to act even before the patient arrives.
Lukovits and an interdisciplinary team of colleagues are also collaborating on three clinical trials to find other ways to treat and prevent the devastating consequences of stroke.
Lukovits is principal investigator at DHMC for a trial called CLOSURE-I, for patients with patent foramen ovale—a hole in the septum, or wall, separating the upper chambers of the heart. The defect allows blood to circulate back to the body without going through the lungs first. If debris is present, it may travel to the brain and cause a stroke. The standard
treatment is blood thinners to reduce the risk of clots. Trial participants are randomly assigned to take standard blood thinners or to get a device implanted to repair the defect. The multicenter trial is sponsored by the device manufacturer.
Another trial, sponsored by the National Institutes of Health, is for patients with narrowed carotid arteries, which supply the brain with blood. The Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST) is comparing carotid endarterectomy, surgical removal of arterial plaque, to stent-assisted carotid angioplasty, in which a tiny balloon is temporarily inflated in the artery and a mesh tube inserted to hold the vessel open. Dr. Richard Powell, a DHMC vascular surgeon, is the principal investigator and DHMC is one of 110 participating centers. It is "the largest trial comparing stenting and endarterectomy ever," says Lukovtis.
Factor: And Lukovits is the principal investigator of a trial DHMC just joined, to determine if Factor VII, a clotting factor typically administered to hemophiliacs, is a safe and effective way to stop bleeding in patients with acute intracerebral hemorrhaging. About 15% of strokes are due to such hemorrhaging. Currently, "there's no proven treatment," says Lukovits.
While Hunt is not participating in any of the trials, she and Lukovits are working hard to ensure that she won't have another stroke. She doesn't smoke or have high blood pressure, two risk factors. But she discovered that she has high cholesterol and diabetes, also risk factors. She's being treated for both.
If you'd like to offer feedback about this article, we'd welcome getting your comments at DartMed@Dartmouth.edu.
This article may not be reproduced or reposted without permission. To inquire about permission, contact DartMed@Dartmouth.edu.